Navigation Links
Daniel K. Spiegelman Elected to Board of Directors of Omeros
Date:12/9/2009

SEATTLE, Dec. 9 /PRNewswire/ -- Omeros Corporation today announced that its Board of Directors has elected Daniel K. Spiegelman to serve on the Company's Board. Mr. Spiegelman has also been appointed to serve as Chairman of the Audit Committee.

"We are very pleased to welcome Dan to our Board and look forward to working with him," stated Gregory Demopulos, M.D., Chairman and CEO of Omeros. "Dan brings a substantial depth and breadth of financial experience in public biotech companies. He will be a valuable asset to Omeros as we prepare to bring our products to market."

"I am excited to be joining Omeros' Board," stated Daniel Spiegelman. "The strength of the Company's management team and pipeline provide significant and multiple opportunities to advance science and improve the lives of patients. I look forward to contributing to the Company's success."

Mr. Spiegelman has over 25 years of executive management, finance and operations experience. He was senior vice president and chief financial officer at CV Therapeutics prior to and during its acquisition by Gilead earlier this year. Prior to that, he was employed by Genentech, where he served as Treasurer and held a number of other senior financial positions. Mr. Spiegelman also serves on the boards of directors and chairs the audit committees of Affymax, Cyclacel Pharmaceuticals and Oncothyreon, all publicly traded biopharmaceutical companies. He earned his M.B.A. from the Stanford Graduate School of Business and his B.A. in economics from Stanford University.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

For more information on Omeros, visit the Company's website at www.omeros.com

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding ability of the Company's management team and pipeline to advance science and improve the lives of patients. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 19, 2009. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.

SOURCE Omeros Corporation


'/>"/>
SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
2. Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
3. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
4. Zyomyx Point-of-Care CD4 Test Selected by CD4 Initiative to Help Treat HIV/AIDS Patients in Developing Countries
5. Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal
6. Sanovia Selected to Deliver PA-Logic(TM) Pharmaceutical Prior Authorization Platform to HealthSpring
7. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
8. Fresenius Medical Care, N.A. Has Selected VitalRemedyMDs VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients
9. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 Progra m ... trial of Oxitec , s mosquito ... Aedes aegypti by 96 %   ... a new plan to fight wild Aedes aegypti, the dangerous mosquito ... on the island of Grand Cayman .  MRCU, a global ...
(Date:5/5/2016)... , May 5, 2016  Diagnostic imaging ... decade due to concerns that these tests cause health ... approach to imaging, as well as the adoption ... era of medical peripherals that help health care providers cut ... Ampronix  advanced medical imaging is a renowned authorized reseller ...
(Date:5/5/2016)... , May 5, 2016 Research ... for PET Imaging in the USA"  report to their ... provides information on the current Positron Emission Tomography (PET) ... USA market. Along with the current known ... USA , the report also contains a ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... TLC Laser Eye Centers announced today that it has acquired Gordon ... be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” , ... ensure that patients continue to receive the highest quality of care. In addition, all ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May ... California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured ...
(Date:5/5/2016)... FRANCISCO (PRWEB) , ... May 05, 2016 , ... ... the Unites States to promise successful results with IVF and with egg freezing, ... to deliver the most patient-centric and highest quality fertility care, Spring Fertility offers ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao ... brown seaweeds. The pair observed that when photosynthetically active radiation (i.e. the white ...
(Date:5/5/2016)... , ... May 05, 2016 ... ... hands-on exercises, the Wharton Seminars for Business Journalists , led by ... of key business and economic issues.  This one-day program at the Wharton ...
Breaking Medicine News(10 mins):